About Vasculitis Treatment
Vasculitis is an autoimmune disorder that causes inflammation of the blood vessels. The body's immune system attacks the blood vessels, which results in inflammation. When this inflammation occurs, the walls of the affected blood vessels get thicker and the passages through which the blood flows get narrower, which reduces the amount of blood and oxygen delivered to vital organs.
Technavio’s analysts forecast the global vasculitis treatment market to grow at a CAGR of 4.20 % during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global vasculitis treatment market for 2017-2021. To calculate the market size, the report considers the sales from the drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Vasculitis Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bristol-Myers Squibb
• CELGENE
• F. Hoffmann-La Roche
• GlaxoSmithKline
Other prominent vendors
• Ablynx
• AB SCIENCES
• Acorda Therapeutics
• Alder Biopharmaceuticals
• Antares Pharma
• Astellas Pharma
• AstraZeneca
• Baxter
• Boehringer Ingelhein
• Can-Fite BioPharma
• Celltrion
• ChemoCentryx
• Coherus BioSciences
• Daiichi Sankyo
• Eisai
• Eli Lilly
• Gilead Sciences
• Hospira
• Idera
• Immunomedics
• ImmuPharma
• Incyte
• Invion
• KaloBios Pharmaceuticals
• Lexicon Pharmaceuticals
• Merck
• MedImmune
• Morphotek
• Novo Nordisk
• Novartis
• Opexa Therapeutics
• Principia
• Regeneron
• Sandoz
• Sanofi
• Santarus
• Takeda
• UCB
• Vaccinex
• Vertex Pharmaceuticals
• Vitae Pharmaceuticals
Market driver
• Promising pipeline
• For a full, detailed list, view our report
Market challenge
• Loss of patent exclusivity of branded therapies
• For a full, detailed list, view our report
Market trend
• Strategic alliances
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Research Methodology
PART 04: Introduction
• Market outline
PART 05: Pipeline landscape
PART 06: Market landscape
• Market overview
• Five forces analysis
PART 07: Market segmentation by drug class
• Corticosteroids
• Immunosuppressants
• Biologics
PART 08: Geographical segmentation
• Vasculitis treatment market in Americas
• Vasculitis treatment market in EMEA
• Vasculitis treatment market in APAC
PART 09: Decision framework
PART 10: Drivers and challenges
• Market drivers
• Market challenges
PART 11: Market trends
• Increase in public awareness programs
• Strategic alliances
• Introduction of novel MOAs
PART 12: Vendor landscape
• Competitive scenario
• Key vendor analysis
• Bristol-Myers Squibb
• CELGENE
• F. Hoffmann-La Roche
• GlaxoSmithKline
• Other prominent vendors
PART 13: Appendix
• List of abbreviations
List of Exhibits
Exhibit 01: Forms of vasculitis based on sizes of blood vessels affected
Exhibit 02: Key clinical trials
Exhibit 03: Global vasculitis treatment market snapshot
Exhibit 04: Global vasculitis treatment market 2016-2021 ($ millions)
Exhibit 05: Opportunity analysis in global vasculitis treatment market
Exhibit 06: Five forces analysis
Exhibit 07: Market segmentation by drug class
Exhibit 08: Global vasculitis corticosteroid drugs market 2016-2021 ($ millions)
Exhibit 09: Global vasculitis immunosuppressant drugs market 2016-2021 ($ millions)
Exhibit 10: Global vasculitis biologics drugs market 2016-2021 ($ millions)
Exhibit 11: Segmentation of global vasculitis treatment market based on geography
Exhibit 12: Global vasculitis treatment market revenue by geography 2016-2021 ($ millions)
Exhibit 13: Market scenario in Americas
Exhibit 14: Vasculitis treatment market in the Americas 2016-2021 ($ millions)
Exhibit 15: Market scenario in EMEA
Exhibit 16: Vasculitis treatment market in EMEA 2016-2021 ($ millions)
Exhibit 17: Opportunity analysis for EMEA
Exhibit 18: Market Scenario of APAC
Exhibit 19: Vasculitis treatment market in APAC 2016-2021 ($ millions)
Exhibit 20: Opportunity analysis for APAC
Exhibit 21: Alternative therapies for vasculitis treatment
Exhibit 22: Adverse effects associated with vasculitis treatment
Exhibit 23: Alliances and agreements
Exhibit 24: List of few pipeline molecules with novel MOAs
Exhibit 25: Competitive structure analysis of global vasculitis treatment market 2016
Exhibit 26: Bristol-Myers Squibb: Key highlights
Exhibit 27: Bristol-Myers Squibb: Strength assessment
Exhibit 28: Bristol-Myers Squibb: Strategy assessment
Exhibit 29: Bristol-Myers Squibb: Opportunity assessment
Exhibit 30: CELGENE: Strength assessment
Exhibit 31: CELGENE: Strength assessment
Exhibit 32: CELGENE: Strategy assessment
Exhibit 33: CELGENE: Opportunity assessment
Exhibit 34: F. Hoffmann-La Roche: Key highlights
Exhibit 35: F. Hoffmann-La Roche: Strength assessment
Exhibit 36: F. Hoffmann-La Roche: Strategy assessment
Exhibit 37: F. Hoffmann-La Roche: Opportunity assessment
Exhibit 38: GlaxoSmithKline: Strength assessment
Exhibit 39: GlaxoSmithKline: Strategy assessment
Exhibit 40: GlaxoSmithKline: Opportunity assessment
